Aduro Clean Technologies Stock (OTC: ACTHF)

Aduro Clean Technologies Stock (OTC:ACTHF), Trade Ideas

Aduro Clean Technologies Inc is a developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into feedstocks and higher-value fuels. The company's technology activates unique properties of water in a chemistry platform that operates at relatively low temperatures and costs.

ADURO CLEAN TECHNOLOGIES by ADURO CLEAN TECHNOLOGIES INC.

Aduro Clean Technologies Inc

According to a recent CBS News poll, 39% of Americans believe the economy is "good," with 57% of respondents viewing the economy as "bad."
It's an issue President Joe Biden has to grapple with as his reelection campaign gears up, especially given that 65% of Americans remember the economy as good under former President Donald Trump, according to the poll.
In August 2022, Biden announced "zero inflation" at a time when the consumer price index (CPI) reported it was 8.5%. While he was referring to 0% month-over-month inflation at the time, it rubbed many the wrong way given the negative perception of the economy, with one Republican senator calling the claim "gaslighting."
Don't Miss:
<ul>
<li>Join the elite. Invest in Epic Games and<a href="https://www.benzinga.com/money/epic-games"> own a piece of the $17 billion Fortnite empire</a>.</li>
<li>This &#8216;Future of Gaming&#8217; startup disrupting a $272 billion industry is<a href="https://www.benzinga.com/money/gameflip-2"> now letting anyone invest for a limited time</a>.</li>
</ul>
While Biden has slightly backed off those claims in the face of still rising inflation, citing "progress" while acknowledging "prices are still too high," a report from the consulting firm McKinsey &amp; Co. uncovered what Americans are now splurging on.
It found that "<a href="https://www.benzinga.com/money/how-much-should-i-spend-on-groceries">groceries were the new biggest splurge category</a>," beating out other more discretionary categories such as eating out, travel and beauty, with millennials being the most likely to count groceries as their biggest luxury.
Trending: Invest alongside execs from Uber, Facebook and Apple in this<a href="https://www.benzinga.com/money/aura"> wellness app Transforming a $5.6 TRILLION dollar industry</a>.
While the same report cited improving consumer optimism about the economy, some commentators found humor that groceries are the biggest splurge category in the face of persistent inflation.
Former American intelligence contractor Edward Snowden posted on X, "The ratchet: first they criticize you for eating avocado toast and then for eating at all."
As many Americans struggle to keep up with the rising prices of necessities, some funds see <a href="https://www.benzinga.com/money/gameflip-2">an opportunity to profit</a>.
Alaska Permanent Fund, the largest U.S state wealth fund, recently disclosed it tripled its stake in Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) and Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), America's two largest grocery players by market share.
Even Warren Buffett's Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) is a big fan of Kroger, owning 6.9% of the grocer.
Keep Reading <a href="https://www.benzinga.com/alternative-investments/startups">About Startups</a>:
<ul>
<li>Invest like a millionaire. Exclusive opportunity to<a href="https://www.benzinga.com/money/epic-games"> invest in Epic Games $17 billion gaming empire.</a></li>
</ul>

General

Biden's Old '0% Inflation' Comment Comes Back To Bite As McKinsey Says New Biggest Splurge For US Consumers Is Groceries

In a surprising turn of events, both proponents and opponents of cannabis reform in Hawaii joined forces to defeat a bill aimed at decriminalizing marijuana further. 
The bill, known as SB2487, would have eased penalties for possession and use of marijuana but was rejected in a vote of 16 to 9 in the state legislature. Sen. Angus McKelvey (D) explained his opposition by highlighting potential risks.
&#8220;The Senate sent a very good, reasonable, <a href="https://www.benzinga.com/markets/cannabis/24/02/37114909/hawaii-senators-approve-cannabis-legalization-bill-despite-internal-opposition-to-governors-pro-">recreational legalization</a> bill with guard rails over to the other chamber. In other states where the rush to decriminalization is outpacing their own recreational medical marijuana market; you could have a black market that could explode. Thereby undercutting and creating all the safety hazards that the bill that we sent over would have addressed,&#8221; McKelvey stated. 
The bill aimed to remove certain penalties under the <a href="https://www.benzinga.com/topic/controlled-substances-act">Uniform Controlled Substances Act</a>, specifically those related to marijuana paraphernalia. It also proposed reducing penalties for the possession and transfer without remuneration of marijuana, concentrates and infused products, while designating public smoking of marijuana as a violation under promoting a detrimental drug in the third degree. Currently, Hawaii has decriminalized possession of up to three grams of cannabis. 
The rejection of SB2487 comes after another failed legislative effort earlier this year when a recreational cannabis bill was killed in the House. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Senate Floor Session 4-22-2024 11:30am" width="500" height="281" src="https://www.youtube.com/embed/HW3agd3Pe54?start=3295&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<figcaption class="wp-element-caption">Senate Floor Session 4-22-2024 11:30am.</figcaption></figure>
<h3 class="wp-block-heading">If They Favor Cannabis, Why Would They Reject The Bill?</h3>
Cannabis regulation isn&#8217;t simply a battle between progressives and conservatives. Advocates for cannabis freedom often support decriminalization, but the complete liberalization of the cannabis market can introduce health and public safety challenges. These concerns are more effectively managed through legalization frameworks. Similarly, substances like alcohol, tobacco and prescription medications are regulated rather than merely decriminalized, just as the personal possession of nearly all plants is subject to legal oversight. 
Hawaiian decriminalization began in early 2020 after an initial attempt to pass a legalization bill failed in the House. There appears to be a consistent approach in the political discussions, which involves a trade-off between pursuing full legalization and expanding consumer rights through decriminalization measures. 
This reflects a strategic legislative effort, balancing the broader goals of legalization against more immediate, albeit limited, advancements. Meanwhile, another piece of legislation concerning cannabis is advancing. A new bill that would establish a pilot program for <a href="https://www.benzinga.com/markets/cannabis/24/04/38110997/hawaii-lawmakers-kill-cannabis-legalization-bill-but-push-decriminalization-expungement">marijuana expungements</a> is headed to the desk of Gov. <a href="https://www.benzinga.com/markets/cannabis/24/02/37022391/hawaii-discusses-cannabis-legalization-governor-says-stoners-are-less-violent-just-hungry-but-co">Josh Green </a>(D-HI). If approved, it could offer some relief and reform, compensate for the technical tie and level the scale a bit once again.

Cannabis

Government

News

Regulations

Hawaii: Cannabis Decriminalization Bill Fails Amid Unified Legislative Opposition

In the preceding three months, 10 analysts have released ratings for Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $41.0, a high estimate of $46.00, and a low estimate of $28.00. This upward trend is apparent, with the current average reflecting a 18.12% increase from the previous average price target of $34.71.
<img src="https://www.benzinga.com/files/images/story/2024/1713895285_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Maplebear. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Morton</td>
<td>MoffettNathanson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Ross Compton</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Nikhil Devnani</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Wolfe Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Maplebear. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Maplebear compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Maplebear's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Maplebear's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CART/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Maplebear analyst ratings.</a>
<h2>Discovering Maplebear: A Closer Look</h2>
Maplebear, which does business as Instacart, is an online grocery pickup and delivery service provider currently in the United States and Canada. Instacart partners with local and national grocers who provide their selection of food and other goods to customers through Instacart's mobile app or website. After a customer places an order, an independent personal shopper employed by Instacart will pick the order and either prepare it for pickup or deliver it to the customer's chosen location. Instacart's revenue model consists of transaction revenue in the form of retailer and customer fees, as well as advertising revenue from brand advertising on Instacart platforms.
<h3>Maplebear's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Maplebear showcased positive performance, achieving a revenue growth rate of 6.08% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Maplebear's net margin is impressive, surpassing industry averages. With a net margin of 16.56%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.68%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Maplebear's ROA stands out, surpassing industry averages. With an impressive ROA of 2.91%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Maplebear's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CART

What 10 Analyst Ratings Have To Say About Maplebear

TScan Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRX#NASDAQ">TCRX</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated TScan Therapeutics and provided 12-month price targets. The average target is $10.75, accompanied by a high estimate of $15.00 and a low estimate of $9.00. Surpassing the previous average price target of $7.00, the current average has increased by 53.57%.
<img src="https://www.benzinga.com/files/images/story/2024/1713895276_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of TScan Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$9.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to TScan Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of TScan Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for TScan Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into TScan Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on TScan Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into TScan Therapeutics's Background</h2>
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
<h3>Breaking Down TScan Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: TScan Therapeutics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 132.99%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: TScan Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -271.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): TScan Therapeutics's ROE excels beyond industry benchmarks, reaching -12.26%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -6.96%, the company showcases effective utilization of assets.
Debt Management: TScan Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 0.61. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TCRX

Unveiling 4 Analyst Insights On TScan Therapeutics

4 analysts have expressed a variety of opinions on Everi Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVRI#NYSE">EVRI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Everi Hldgs and provided 12-month price targets. The average target is $12.25, accompanied by a high estimate of $13.00 and a low estimate of $11.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 18.33%. 
<img src="https://www.benzinga.com/files/images/story/2024/1713895256_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Everi Hldgs among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Bain</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>David Katz</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Everi Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Everi Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Everi Hldgs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Everi Hldgs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EVRI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Everi Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Everi Hldgs's Background</h2>
Everi Holdings Inc provides entertainment and technology solutions for the casino, interactive, and gaming industry. It operates in two segments namely Games and Financial Technology Solutions (FinTech). Enveri Games provides gaming operators with gaming technology products and services which include gaming machines, slot machines, leased gaming equipment, and other products and services. Enveri FinTech provides gaming operators with financial technology products and services which include services and equipment that facilitate casino patron's to access cash at gaming facilities through automated teller machines, point of sale debit card purchases and others.
<h3>Financial Milestones: Everi Hldgs's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Everi Hldgs's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -6.49%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Everi Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Everi Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of 0.81%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Everi Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.09% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Everi Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 4.34, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EVRI

Analyst Scoreboard: 4 Ratings For Everi Hldgs

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $96.5, a high estimate of $109.00, and a low estimate of $85.00. This upward trend is evident, with the current average reflecting a 6.63% increase from the previous average price target of $90.50.
<img src="https://www.benzinga.com/files/images/story/2024/1713895242_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Pinnacle Finl Partners by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Olney</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$109.00</td>
<td>-</td>
</tr>
<tr>
<td>Casey Haire</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$93.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Pinnacle Finl Partners. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Pinnacle Finl Partners compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Pinnacle Finl Partners's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pinnacle Finl Partners's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PNFP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pinnacle Finl Partners analyst ratings.</a>
<h2>Get to Know Pinnacle Finl Partners Better</h2>
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. Pinnacle operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
<h3>Unraveling the Financial Story of Pinnacle Finl Partners</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Pinnacle Finl Partners's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -33.55%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Pinnacle Finl Partners's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 39.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Pinnacle Finl Partners's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.59%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Pinnacle Finl Partners's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.19%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Pinnacle Finl Partners's debt-to-equity ratio is below the industry average at 0.44, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PNFP

Cracking The Code: Understanding Analyst Reviews For Pinnacle Finl Partners

ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.8, with a high estimate of $83.00 and a low estimate of $72.00. Observing a 9.19% increase, the current average has risen from the previous average price target of $71.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1713895233_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of ANI Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Gregory Fraser</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Gregory Fraser</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$72.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ANI Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ANI Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of ANI Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into ANI Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANIP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ANI Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About ANI Pharmaceuticals</h2>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>ANI Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: ANI Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 39.71%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: ANI Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 0.57%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ANI Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.17% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): ANI Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 0.08%. This signifies efficient management of assets and strong financial health.
Debt Management: ANI Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.66.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANIP

Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts

Applied Digital's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NYSE">APLD</a>) short percent of float has risen 9.17% since its last report. The company recently reported that it has 21.13 million shares sold short, which is 21.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Applied Digital Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713895227_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Applied Digital has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Applied Digital's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Applied Digital's peer group average for short interest as a percentage of float is 5.66%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

APLD

How Is The Market Feeling About Applied Digital?

Natera's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NYSE">NTRA</a>) short percent of float has fallen 21.4% since its last report. The company recently reported that it has 6.25 million shares sold short, which is 5.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Natera Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713895221_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Natera has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Natera's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Natera's peer group average for short interest as a percentage of float is 5.96%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NTRA

Looking Into Natera's Recent Short Interest

New York Community's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>) short percent of float has risen 12.26% since its last report. The company recently reported that it has 75.57 million shares sold short, which is 10.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>New York Community Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713895216_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for New York Community has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing New York Community's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, New York Community's peer group average for short interest as a percentage of float is 4.93%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NYCB

Peering Into New York Community's Recent Short Interest

In the latest quarter, 5 analysts provided ratings for Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $46.2, a high estimate of $57.00, and a low estimate of $35.00. This current average reflects an increase of 52.32% from the previous average price target of $30.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1713895212_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Beam Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$42.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$35.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Beam Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Beam Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Beam Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Beam Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BEAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Beam Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Beam Therapeutics</h2>
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
<h3>Key Indicators: Beam Therapeutics's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Beam Therapeutics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 1478.04%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Beam Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 45.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Beam Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.22% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Beam Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.38% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Beam Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BEAM

Expert Ratings For Beam Therapeutics

WIIM

BLDR

Builders FirstSource shares are trading higher. Building products companies may be higher following better-than-expected new home sales data.

Shares of Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) fell sharply during Tuesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/04/38365860/nucor-shares-fall-after-worse-than-expected-q1-results">quarterly financial results</a>.
Nucor reported quarterly earnings of $3.46 per share which missed the analyst consensus estimate of $3.65. Quarterly sales came in at $8.14 billion, missing the analyst consensus estimate of $8.26 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Nucor shares tumbled 6.5% to $179.20 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares jumped 100% to $0.2419 after the company announced that it has been chosen to supply its DriveMod Tuggers for industrial automation to John Deere&#8217;s operation in Dubuque, Iowa.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares climbed 50.4% to $0.0689 after falling 10% on Monday.</li>
<li>Oportun Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>) gained 46% to $3.29 after the company announced preliminary first-quarter total revenue above estimates.</li>
<li>Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares climbed 44.3% to $7.12 after the company entered a collaboration with Strand Life Sciences.</li>
<li>KULR Technology Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NASDAQ">KULR</a>) gained 27% to $0.5683 after the company announced it delivered on an immediate basis, a power cell battery deployment order for AI-enabled drone and advanced air mobility missions in Ukraine.</li>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) climbed 20% to $5.22.</li>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) rose 19.5% to $1.5307 after declining 3% on Monday.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) gained 18.7% to $9.49.</li>
<li>Hibbett, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) rose 18.4% to $85.85 after the company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transaction.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) gained 17.4% to $1.3499.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) rose 15.5% to $9.24.</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) gained 15.5% to $0.9295.</li>
<li>Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) climbed 15.2% to $2.20.</li>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares gained 15% to $0.2244 after the company announced new preclinical data will be presented at the American Society of Gene and Cell Therapy meeting.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) jumped 14.4% to $0.8603.</li>
<li>9F Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFU#NASDAQ">JFU</a>) rose 14.3% to $3.29.</li>
<li>Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) gained 14% to $1.05. The company executives announced intentions to purchase at least $2 million of the company's common stock.</li>
<li>Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) jumped 12.7% to $20.59 after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) gained 12.3% to $305.73 following first-quarter financial results.</li>
<li>Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) climbed 11.6% to $2.89 after Capital One initiated coverage on the stock with an Overweight rating and $6 price target.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) gained 9.4% to $6.05.</li>
<li>Ryder System, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) rose 9% to $118.82 following better-than-expected quarterly earnings.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) jumped 8.8% to $10.15.</li>
<li>HealthStream, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) surged 7.4% to $25.91 following upbeat quarterly results.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares rose 7% to $0.55 following upbeat quarterly results.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) gained 6.2% to $62.20.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) fell 48.4% to $3.7950 after the company announced the FDA issued a Complete Response Letter in response to the company&#8217;s Biologics License Application for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares fell 44.6% to $0.0699. Greenwave Technology Solutions disclosed that it further strengthened its balance sheet by approximately $12 million.</li>
<li>Lichen China Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) fell 44.4% to $0.5450.</li>
<li>Tungray Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRSG#NASDAQ">TRSG</a>) shares declined 34.2% to $4.87 after gaining 24% on Monday.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) fell 26.3% to $0.5091.</li>
<li>Moolec Science SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLEC#NASDAQ">MLEC</a>) fell 24.3% to $1.87. On April 22, Moolec Science said it received approval for its plant-grown animal proteins.</li>
<li>YY Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYGH#NASDAQ">YYGH</a>) fell 22.4% to $2.25 after tumbling over 27% on Monday. The company, last week, priced its IPO at $4 per share.</li>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) dipped 19.7% to $2.0899.</li>
<li>Comstock Holding Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHCI#NASDAQ">CHCI</a>) declined 18.8% to $6.44.</li>
<li>SuperCom Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) dipped 18% to $0.2369. SuperCom recently reported better-than-expected quarterly results.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) declined 16.2% to $6.29 after the company reported first-quarter financial results and issued worse-than-expected Q2 and FY24 Revenue outlook.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) declined 13% to $448.01 following first-quarter financial results.</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) fell 12.6% to $42.78 after the company reported a first-quarter earnings miss and cut its FY24 outlook.</li>
<li>Simpson Manufacturing Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) dipped 11.7% to $163.40 following weak quarterly earnings.</li>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares fell 11.2% to $0.1598 after the company filed for a mixed shelf offering of up to $75 million.</li>
<li>Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) tumbled 11.1% to $14.60 after the company reported worse-than-expected first-quarter results and reiterated FY24 guidance.</li>
<li>T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) declined 10.4% to $2.83 after gaining around 7% on Monday.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) shares fell 10.1% to $7.13 after the company issued its production and sales performance metrics for the nine months ended 31 March, 2024.</li>
<li>Complete Solaria, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) fell 9.3% to $0.3530 after dipping around 14% on Monday.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) dipped 7.8% to $19.22 after the company&#8217;s reported worse-than-expected first-quarter financial results.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) fell 7.1% to $0.77. Phio Pharmaceuticals shares jumped around 33% on Monday after the company announced that its intratumoral injection of murine PH-762 inhibited tumor growth in murine tumor models and may generate memory-specific T cells.</li>
<li>Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) shares fell 4.1% to $28.34 after the company reported mixed first-quarter financial results and issued second-quarter guidance below estimates.</li>
</ul>
Read More: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38379861/bitcoin-surpasses-66-000-akash-network-core-among-top-gainers">Bitcoin Surpasses $66,000; Akash Network, Core Among Top Gainers</a>

Intraday Update

Markets

Movers

ABEO

AZTR

CALX

CDTX

CHCI

CSLR

CTCX

FCEL

GWAV

HIBB

HRTX

HSTM

JAGX

JBLU

KULR

LICN

MESO

MLEC

MSCI

OPRT

PALI

PEGY

PHIO

RNAC

ROKU

SMFL

SMXT

SPCB

SPCE

SPOT

TIRX

TRSG

TTOO

YYGH

Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Western Digital shares are trading higher amid overall strength in tech.

Offerings

LIXT

Lixte Biotechnology Holdings Files $50M Offering

RTX Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) reported a first-quarter FY24 adjusted net sales increase of 12% Y/Y to $19.3 billion,&nbsp;beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38374759/rtx-reports-q1-2024-results" rel="noreferrer noopener">consensus of $18.4 billion</a>.&nbsp;
Collins&nbsp;Aerospace&#8217;s&nbsp;sales were $6.7 billion (+9% Y/Y), driven by a 14% increase in commercial aftermarket and commercial OE and a 1% increase in defense. The adjusted operating margin expanded by 90 bps Y/Y to&nbsp;15.7%.
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/02/37259825/rtxs-collins-aerospace-to-elevate-air-indias-737-max-fleet-with-advanced-avionics-package-detail" rel="noreferrer noopener">RTX&#8217;s&nbsp;Collins Aerospace To Elevate Air&nbsp;India&#8217;s&nbsp;737 MAX Fleet with Advanced Avionics Package: Details</a>
Pratt &amp;&nbsp;Whitney&#8217;s&nbsp;sales were $6.46 billion (+23% Y/Y), driven by a 64% increase in commercial OE,&nbsp;a 21% increase in military, and&nbsp;a 9% rise in commercial aftermarket business.&nbsp;Adjusted&nbsp;operating margin of 6.7%, down by 160&nbsp;bps.
Raytheon&#8217;s&nbsp;sales increased by 6% Y/Y to $6.66 billion, driven by higher volume on land and air defense systems. The adjusted operating margin expanded by 20 bps to 9.5%.
Adjusted EPS improved 10% Y/Y to $1.34, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $1.23</a>.
At the end of the quarter, the backlog was $202 billion, of which $125 billion was from commercial aerospace and $77 billion was from defense.
RTX&#8217;s&nbsp;operating cash flow for the quarter totaled $0.3 billion, and a free cash outflow of&nbsp;$(0.1) billion.
FY24 Outlook Reiterated:&nbsp;RTX expects sales of $78 billion-$79 billion, versus the consensus of $78.78 billion; sees adjusted EPS of $5.25 – $5.40&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/01/36741472/why-is-aerospace-and-defense-giant-rtx-stock-rallying-today" rel="noreferrer noopener">versus the consensus of $5.39</a>.&nbsp;
The company expects a&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">free cash flow of ~$5.7 billion&nbsp;in the year</a>.
Last week, RTX entered into an energy supply agreement with a&nbsp;subsidiary of&nbsp;ENGIE North America,&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/04/38318444/rtx-inks-largest-renewable-electricity-agreement-on-path-to-achieve-2025-goal" rel="noreferrer noopener">ENGIE Resources LLC&nbsp;(ENGIE)</a>.
Earlier this month, Pratt &amp; Whitney launched NATA in Florida, enhancing&nbsp;MRO&nbsp;network with&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38169506/whats-going-on-with-pratt-whitney-parent-rtx-shares-today" rel="noreferrer noopener">dedicated space and resources</a>.
Price Action: RTX shares are trading higher by 0.08% at $101.64 at the last check Tuesday.
Photo via Shutterstock

Earnings

Equities

Large Cap

Guidance

RTX Soars Above Estimates in Q1, Reiterates FY24 Outlook

Healthcare did not have a great 2023, even as markets turned around from the depths of the year prior. The sector, which roughly accounts for 13% of the S&amp;P 500, lagged last year as investors flocked to massive tech and growth stocks that propelled the markets. A late-year rally in 2023 saw the sector pairing its losses for the year and ending the 12 months on a positive note, even if only just. The turnaround, however, did not stop it from becoming one of the S&amp;P 500&#39;s worst-performing sectors in 2023, rising just 0.3% compared to the benchmark index&#39;s 24% jump.
Yet, upsides are being witnessed for the sector of late. Health spending in the United States has been forecast to grow at an average annual rate of 5.4% for 2019-2028 and should reach $6.2 trillion by 2028. While the industry faces labor shortages and recessionary pressures in the post-pandemic world marked by a European war, it is currently pitted to grow at a higher rate than the overall economy.
Globally, approximately $8.3 trillion is being spent on healthcare, with almost half of that, roughly $3.8 trillion, coming from the United States. Considering the fact that the healthcare sector is growing faster than the overall world economy, these figures are expected to rise substantially by the turn of the decade.
Several societal and demographic upheavals are also aiding the sector. These include an aging population and epidemics like obesity and diabetes. Moreover, these stocks are considered defensive, meaning they tend to remain stable regardless of the prevalent market conditions. Regular demand for healthcare services is not dependent on the peaks and troughs of a market that has risen and fallen over the past two years over the Fed&#39;s monetary policy.
Also, the healthcare sector is poised for significant long-term changes, including the integration of AI in medical research. The sector also seems lucrative for investors looking for a steady cash flow because pharmaceutical companies are known to offer regular dividends.
Healthcare has also seen growth in the ETF market in 2024. The S&amp;P 500 Select Sector SPDR for Healthcare (ARCA:XLV) grew 2.4% in March. It has jumped 8.8% in the first quarter and 16% over the last 12 months. The sector may be off its pandemic-period peak but will remain resilient and grow in the coming years.
Hence, astute investors should bet on healthcare mutual funds at present. Mutual funds, in general, reduce transaction costs and diversify portfolios without an array of commission charges that are mostly associated with stock purchases.
We have thus selected three such healthcare mutual funds that boast a Zacks Mutual Fund Rank #1 (Strong Buy), 2 (Buy), have positive three-year and five-year annualized returns, minimum initial investments within $5000, and carry a low expense ratio.
Janus Henderson Global Life Sciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jnglx#NASDAQ">JNGLX</a>) primarily invests in equity securities issued by companies engaged in life sciences orientation.
Andrew Acker has been the lead manager of JNGLXsince April 2007. The fund has 6.5% of its portfolio invested in UnitedHealth Group, 5.1% in Eli Lilly and 4.2% in Novo Nordisk.
JNGLX&#39;s 3-year and 5-year annualized returns are 7.6% and 11.6%, respectively. Its net expense ratio is 0.80%. JNGLXhas a Zacks Mutual Fund Rank #2.
Vanguard Health Care (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vghcx#NASDAQ">VGHCX</a>) primarily invests in stocks of companies principally engaged in the development, production, or distribution of products and services in the healthcare industry. VGHCX also invests a significant portion of its assets in foreign stocks.
Jean M. Hynes has been the lead manager of VGHCX since May 2008. The fund has 8% of its portfolio invested in Eli Lilly, 7.8% in UnitedHealth Group and 5.7% in AstraZeneca.
VGHCX&#39;s 3-year and 5-year annualized returns are 7.9% and 9.9%, respectively. Its net expense ratio is 0.36%. VGHCX has a Zacks Mutual Fund Rank #1.
Fidelity Select Pharmaceuticals Portfolio (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fphax#NASDAQ">FPHAX</a>) primarily invests in stocks of companies principally engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. FPHAX advisors use fundamental analysis of factors like each issuer&#39;s financial condition and industry position, as well as market and economic conditions, to arrive at their investment decision.
Karim Suwwan de Felipe has been the lead manager of FPHAX since June 2017. The fund has 24.1% of its portfolio invested in Eli Lilly, 14.8% in Novo Nordisk and 9.4% in AstraZeneca.
FPHAX&#39;s 3-year and 5-year annualized returns are 13.2% and 14%, respectively. Its net expense ratio is 0.73%. FPHAX has a Zacks Mutual Fund Rank #1.
<a href="https://www.zacks.com/stock/news/2259787/3-healthcare-mutual-funds-to-grab-as-the-sector-continues-to-rebound?cid=CS-BENZ-FT-mutual_fund_commentary-2259787">To read this article on Zacks.com click here.</a>

Mutual Funds

Health Care

FPHAX

JNGLX

Vanguard Specialized Portfolios Health Care Fund

VGHCX

3 Healthcare Mutual Funds To Grab As the Sector Continues to Rebound

Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) is set to report its fiscal fourth-quarter (F4Q) earnings on May 7 after the market closes. With the gaming landscape facing macroeconomic headwinds and specific challenges, EA&#8217;s upcoming earnings are <a href="https://www.benzinga.com/topic/video-games">approached with moderated expectations</a>.
EA Analysts&#8217; Overview: Oppenheimer analysts Martin Yang, CFA, and Andrew Northcutt continue to rate EA as Outperform with a price target of $150. 
Despite current market challenges, they believe EA&#8217;s valuation provides decent downside protection.
See Also: <a href="https://www.benzinga.com/general/gaming/24/04/38226663/ea-drops-uk-quality-team-leaves-40-apex-legends-staffers-in-limbo">EA Drops UK Quality Team, Leaves 40 Apex Legends Staffers In Limbo</a>
Moderated Expectations: The analysts have adjusted their outlook, anticipating EA&#8217;s performance to align with conservative guidance due to softer live service bookings and a leaner release slate. 
&#8220;We see investor sentiment as neutral to slightly negative into EA&#8217;s F4Q24 earnings,&#8221; Martin Yang noted, attributing the sentiment to the subdued macro outlook on the console game market and performance issues in titles like Apex Legends.
Strategic Overview:
<ul>
<li>Game Releases: EA plans to bolster its portfolio with highly anticipated titles such as College Football, Need for Speed, and Dragon Age Dreadwolf.</li>
<li>Digital and Mobile Growth: Continued expansion in digital sales and mobile gaming platforms is expected, leveraging strong franchises and new content.</li>
<li>Hardware Sales: The company also anticipates a rebound in gaming hardware sales as next-generation consoles gain traction.</li>
</ul>
Revenue and Profit Outlook:
<ul>
<li>Revenue Streams: Although live services are experiencing slower growth, EA&#8217;s digital segment is expected to maintain its expansion, supported by ongoing user engagement.</li>
<li>Margin Expansion: Improvements in game development and marketing efficiency are likely to enhance margins.</li>
</ul>
Investor Catalysts: The analysts highlight several factors that could positively influence investor sentiment:
<ul>
<li>New game launches and a strategic focus on digital transformation are expected to reinforce EA&#8217;s market position.</li>
<li>Potential small-scale mergers and acquisitions are viewed as opportunities for strategic growth and innovation.</li>
</ul>
Looking Ahead: For the F4Q report, Yang and Northcutt predict a cautious yet strategic approach, with discussions on new initiatives likely during the earnings call, especially relating to EA&#8217;s digital and mobile strategies.
Market Position: &#8220;With a clearer catalyst path into C2H24, we view EA as a better buy than Take-Two Interactive Software Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>), in the near term,&#8221; the analysts said.
EA Price Action: Electronic Arts stock was trading at $127.50 at the time of publication, up 0.32% in the past 24 hours, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro. </a>
Read Next: <a href="https://www.benzinga.com/news/24/04/38185551/ea-raising-price-of-ea-play-subscription-games-industry">&#8216;EA Raising Price Of EA Play Subscription&#8217; </a>
Image credits: <a href="https://www.shutterstock.com/es/g/Sergei_Elagin">Sergei Elagin</a> on Shutterstock.

Gaming

Previews

TTWO

Can Electronic Arts Overcome Gaming Headwinds? What To Expect From Upcoming Q4 Earnings

Monness, Crespi, Hardt analyst Jim Chartier downgrades Hibbett (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) from Buy to Neutral.

Downgrades

Monness, Crespi, Hardt Downgrades Hibbett to Neutral

SNDL's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NYSE">SNDL</a>) short percent of float has fallen 6.62% since its last report. The company recently reported that it has 10.40 million shares sold short, which is 3.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>SNDL Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713894321_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SNDL has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing SNDL's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, SNDL's peer group average for short interest as a percentage of float is 11.46%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SNDL

Peering Into SNDL's Recent Short Interest

Aduro Clean Technologies expands presence in Europe

These Industrials stocks are trading higher:-Terran Orbital Corp (LLAP) stock is trading at $1.35, an increase of $0.21, or 17.98%, on high volume.  Terran Orbital Corporation gets a Sentiment Score of Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $5.03.

Industrials Stocks Moving Tuesday: LLAP, ACTHF, ZIM, FLUX, SIDU, AMPX, TBLT, SATL

ACTHF

AMPX

FLUX

LLAP

SATL

SIDU

TBLT

Contracts

Press Releases

Aduro Clean Technologies Expands Technology Evaluation Scope with Leading Petrochemical Company

Financing

Aduro Clean Technologies Presents at CEM AlphaNorth Capital Event and Extends Engagement with Arrowhead Business and Investment Decisions

Aduro Clean Technologies Engages Crystal Research Associates to Provide Marketing and Investor Relations Services

Aduro Clean Technologies Featured on Viewpoint with Dennis Quaid

Aduro Clean Technologies Shares Sample Test Results from its Continuous Flow Unit Experimentation and Optimization Program

Aduro Clean Technologies Announces Upcoming Conference Schedule and Engagement of Outside The Box Capital to Provide Marketing and Investor Relations Services

Aduro Clean Technologies Welcomes a Global Multinational Food Packaging Company into its Customer Engagement Program

Aduro Clean Technologies Welcomes a Multinational Building Materials Company into its Customer Engagement Program

Aduro Clean Technologies Provides Update on Joint Western University Research Project

Aduro Clean Technologies to Present at European Recycling and Renewable Materials Conferences

Aduro Clean Technologies